Serplulimab represents a significant advance in immunotherapy , acting as a novel PD-L1 blocker designed to inhibit the interaction between PD-L1 and its receptor . This action facilitates the patient's https://lancejlcc666228.mpeblog.com/73945402/serplulimab-a-innovative-immune-blocker-for-malignancy-treatment